Intravacc BV has been awarded funding for up to $633,000 from CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) for the development of a preventive vaccine against Neisseria gonorrhoeae (NG), the bacterium that causes gonorrhea.